In a study reported in the Journal of Clinical Oncology, Litton et al found that 6 months of neoadjuvant talazoparib therapy resulted in a high rate of pathologic complete response in patients with stage I–III breast cancer with germline pathogenic BRCA mutations.
Pregnancy after breast cancer appears to be safe in patients with germline BRCA mutations—and particularly among those with BRCA1 mutations...
In a study reported in The Lancet, the Collaborative Group on Hormonal Factors in Breast Cancer found that the use of menopausal hormone therapy is associated with an increased risk of breast cancer, with risk increasing as duration of use increases, in both current and past users.
In a statement published in JAMA, the U.S. Preventive Services Task Force (USPSTF) recommended that clinicians offer to prescribe risk-reducing medications to women who are at an increased risk of breast cancer and at low risk of adverse events related to medications. However, the Task Force recommended against the routine use of risk-reducing medications in women who are not at an increased risk of breast cancer.
In the phase Ib NSABP Foundation Trial FB-10 reported in the Journal of Clinical Oncology, Abraham et al found evidence of activity of the combination of ado-trastuzumab emtansine (T-DM1) plus neratinib in metastatic HER2-positive breast cancer and identified the dose of the combination for phase II testing.